Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we unmask the hidden interference in filariasis testing?

NCT ID NCT04258670

Knowledge-focused Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This study investigates why people with loiasis, a parasitic infection, may test positive on rapid diagnostic tests for lymphatic filariasis. Researchers will follow 60 individuals with high loiasis worm burdens to monitor the release of filarial antigens in their blood. By identifying these cross-reactive proteins, the study aims to improve the accuracy of diagnostic tests for lymphatic filariasis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could identify specific biomarkers to improve diagnostic tests, reducing false positives for lymphatic filariasis in regions where loiasis is common.
What could go wrong
This is an observational study with a small sample size, and findings may not generalize to all populations. The cross-reactive antigens may vary over time, complicating biomarker identification.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

86 people

The number who actually took part.

Started

Jan 2020

Finished

May 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will be conducted in the Okola health district (Lékié Division, Centre Region, Cameroon), situated about 40km northeast of Yaoundé, the political capital city of Cameroon. The Okola health district is highly endemic for loiasis. Participant will be recruited among those excluded from an Onchocerciasis study due to high Mf counts \>20,000/mL.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability to give informed consent * Loiasis Mf count \> 20,000 Mf/mL * Resident of study area * No evidence of severe or systemic comorbidities * Consent to storage of blood samples for future study Exclusion Criteria: * Subject plans to move from the study area during subsequent 12 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Loiasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

filarial elephantiasis filariasis loiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Loiasis Lymphatic filariasis

Contacts and locations

Locations

  • Centre for Research on Filariasis and other Tropical Diseases (CRFilMT)

    Yaoundé, Cameroon

More trials for these conditions

Other studies related to the condition(s) this trial covers.